College of Pulmonary and Critical Care Medicine, the 8th Medical Center of Chinese PLA General Hospital, Beijing, China.
Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
J Med Case Rep. 2024 Sep 29;18(1):451. doi: 10.1186/s13256-024-04790-y.
Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia.
A 60-year-old Asian male with no history of thrombocytopenia was administered with nintedanib to treat progressive pulmonary fibrosis. The platelet count dropped rapidly after introduction of nintedanib and resolved gradually by withdrawal of the medication along with thrombopoietin receptor agonist.
Based on experience from the limited reports, nintedanib-induced thrombocytopenia is typically reversible and manageable. Close monitoring of platelet counts in patients receiving this medication should be warranted.
尼达尼布是一种主要的抗纤维化药物，可用于特发性肺纤维化、系统性硬化症-间质性肺病和进行性肺纤维化，有散在的药物引起血小板减少症的报告。
一名 60 岁亚洲男性，无血小板减少症病史，接受尼达尼布治疗进行性肺纤维化。尼达尼布使用后血小板计数迅速下降，停药并使用血小板生成素受体激动剂后逐渐恢复。
根据有限报告的经验，尼达尼布引起的血小板减少症通常是可逆的且可治疗。应密切监测接受这种药物治疗的患者的血小板计数。
